Seeking Alpha


Send Message
View as an RSS Feed
View bil4Bill's Comments BY TICKER:

Latest  |  Highest rated
  • Sarepta Therapeutics Setting Up For Another Move Upward [View article]
    the bulls are correct.
    Jan 31, 2013. 03:57 PM | 1 Like Like |Link to Comment
  • Alkermes (ALKS): Q4 EPS of $0.34 beats by $0.11. Revenue of $135.9M (+8.2% Y/Y) beats by $5.09M. (PR[View news story]
    give alks time.

    it is going much higher.
    Jan 31, 2013. 12:29 PM | Likes Like |Link to Comment
  • Isis (ISIS) +9.2% after the FDA approved its Kynamro drug to treat HoFH, a rare genetic disorder that causes extremely high cholesterol and heart attacks by the age of 30. While the drug is unlikely to be a blockbuster, it could be the first commercially viable medicine to use antisense technology, which can close down specific genes that cause disease and could have unlimited other uses. Partner Sanofi (SNY) is +1%, while it might also be worth watching antisense peer Sarepta (SRPT). [View news story]
    don't just watch srpt.

    buy it!
    Jan 30, 2013. 06:51 PM | Likes Like |Link to Comment
  • Amazon (AMZN -0.3%) adds a service for developers to help them design games in which users can use their Amazon accounts to purchase virtual goods and currency. Though not yet a dominant force in the gaming market, Amazon's long reputation in e-commerce is seen as helping it shoulder into the in-apps purchasing market. [View news story]
    shades of just before the dot-com bust 12 years ago!
    Jan 22, 2013. 12:45 PM | Likes Like |Link to Comment
  • Shares of Alkermes (ALKS -0.4%) fail to get a spark from todays buying, largely due to Credit Suisse initiating the stock with a tepid Neutral rating and lackluster $24 price target. The firm says ALKS has an enticing long-term story, but its recent run (the stock is already +21% YTD versus +7% for its peers) leaves the broker looking for a better entry point. Additionally, a potentially negative readout for its depression drug candidate ALKS 5461 poses near-term risks. [View news story]
    a great company with huge long term potential.

    if you are a long term investor looking for big profits, go with the tide and not short term ripples in the water.

    former long term early holder of genentech, amgen,etc.
    Jan 18, 2013. 12:32 AM | Likes Like |Link to Comment
  • Sarepta (SRPT +2.4%) CEO Chris Garabedian told the JPM healthcare conference yesterday (transcript) that his company's cash balance at the end of Q4 was $187M. Sarepta plans to meet the FDA in Q1 over its Eteplirsen drug for muscular dystrophy for end of Phase II discussions. If the talks are "favorable," Sarepta will look to file for an accelerated approval for the drug, which Garabedian reckons has a market of $600M-$1B in the U.S. [View news story]
    cheap stock.

    enormous potenyial!
    Jan 10, 2013. 04:32 PM | Likes Like |Link to Comment